Arch Dis Child. 1978 Feb;53(2):112-9.
This report presents results of the first multicentre study of the treatment of nephroblastoma in the United Kingdom. Of 114 children entered in the trial, 108 with localised tumours and without identified metastases were treated by nephrectomy and a 4-day course of actinomycin D, followed by radiotherapy: they were then allocated randomly either to receive further courses of actinomycin D or to receive vincristine for a period of 2 years from diagnosis. The children have so far been followed for periods of between 27 and 69 months; at this stage the superiority of vincristine (in the dose given) to further actinomycin D in preventing local recurrence and metastasis borders on significance; the difference between survival rates also suggests an advantage for vincristine but is not statistically significant. The actuarial survival and continuous disease-free rates at 2 years were 77·7% and 53·6% respectively in the actinomycin D group compared with 87·8% and 79·4% in the vincristine group.
本报告展示了英国首次针对肾母细胞瘤治疗的多中心研究结果。在参与该试验的114名儿童中，108名患有局限性肿瘤且未发现转移，他们接受了肾切除术及为期4天的放线菌素D治疗，随后进行放疗；之后，这些儿童被随机分配，要么接受进一步的放线菌素D疗程，要么从确诊开始接受为期2年的长春新碱治疗。到目前为止，对这些儿童的随访时间在27至69个月之间；在此阶段，长春新碱（在所给剂量下）在预防局部复发和转移方面优于进一步使用放线菌素D，这一差异接近显著水平；生存率之间的差异也表明长春新碱具有优势，但在统计学上并不显著。放线菌素D组2年的精算生存率和持续无病率分别为77.7%和53.6%，而长春新碱组分别为87.8%和79.4%。
